Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4538637 | 0.81 | LTA4H (0.40) | LTA4HCYP1A2CYP3A4MEN1KMT2A | |
| SCHEMBL6199543 | 0.78 | HTR1A (0.36) | CA2HTR1A | |
| SCHEMBL4336064 | 0.77 | CA2 (0.32) | LTA4HCA2HTR1AADRA1A | |
| SCHEMBL4341944 | 0.74 | HTR1A (0.33) | CYP3A4CYP2C19CA2HTR1A | |
| SCHEMBL6799604 | 0.73 | HTR1A (0.34) | CYP3A4CYP2C19CA2HTR1A | |
| SCHEMBL5765990 | 0.73 | LMNA (0.38) | CYP3A4CYP2D6TSHRCYP2C19CA2 | |
| SCHEMBL4907152 | 0.71 | HTR1A (0.55) | CYP3A4CYP2C19HTR1A | |
| SCHEMBL4197898 | 0.71 | HTR1A (0.55) | CYP3A4CYP2C19HTR1A | |
| SCHEMBL6864820 | 0.70 | DRD4 (0.45) | MEN1KMT2AHTR1A | |
| Hydrochloric Acid SCHEMBL5508210 | 0.70 | HTR1A (0.54) | CYP3A4CYP2C19HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042895-A1 | Antidepressant Piperidine Derivatives of Heterocycle-Fused Benzodioxans | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-7479500-B2 | Antidepressant piperidine derivatives of heterocyclefused benzodioxans | WYETH (US) | 2009-01-20 | — | — | US | disclosed |
| WO-2008150848-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2008-12-11 | — | — | WO | disclosed |
| US-7419986-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7335666-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1537122-B9 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH CORP (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1537122-B1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070004702-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-12-28 | — | — | US | disclosed |
| US-20040077652-A1 | Treating obsessive compulsive disorder, panic attacks, sexual disorders, eating disorders, obesity, drug abuse and ethanol or cocaine dependence; anxiolytic agents | WYETH | 2004-04-22 | — | — | US | disclosed |
| WO-2004024733-A1 | ANTIDEPRESSANT PIPERIDINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024732-A1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024731-A1 | ANTIDEPRESSANT ARYLPIPERAZINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024730-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024734-A1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-1381614-A2 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-f]QUINOXALINE | Wyeth (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6617327-B2 | For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-09-09 | — | — | US | disclosed |
| US-20020183329-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002088144-A2 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-f]QUINOXALINE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, HTR5A, DBH | LTA4H 3013/4885CYP1A2 73/4885CYP3A4 285/4885 |
| US-20040077652-A1 | Treating obsessive compulsive disorder, panic attacks, sexual disorders, eating disorders, obesity, drug abuse and ethanol or cocaine dependence; anxiolytic agents | OPRD1, DRD1, ADH1A | LTA4H 4241/4885CYP1A2 331/4885CYP3A4 688/4885 |
| US-20020183329-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline | OPRD1, OPRK1, DRD2 | LTA4H 4248/4885CYP1A2 135/4885CYP3A4 675/4885 |
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | HTR5A, CRH, CYP17A1 | LTA4H 3949/4885CYP1A2 61/4885CYP3A4 203/4885 |
| US-20070004702-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, CYP19A1, HTR5A | LTA4H 3273/4885CYP1A2 71/4885CYP3A4 235/4885 |
| US-20090042895-A1 | Antidepressant Piperidine Derivatives of Heterocycle-Fused Benzodioxans | HTR5A, OPRD1, CRH | LTA4H 3974/4885CYP1A2 140/4885CYP3A4 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.